L3VLUP
ProSign in

RYTM · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

RYTMLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • RYTM
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterRYTMLLY
Q3 20201 holders, $95m33 holders, $14.1bn
Q4 20201 holders, $134m29 holders, $17.3bn
Q1 20211 holders, $87m24 holders, $23.0bn
Q2 20211 holders, $77m24 holders, $27.8bn
Q3 2021none listed holders, n.a.31 holders, $29.9bn
Q4 20211 holders, $593k31 holders, $34.7bn
Q1 20221 holders, $474k24 holders, $35.3bn
Q2 20221 holders, $628k33 holders, $42.7bn
Q3 20222 holders, $43m31 holders, $43.4bn
Q4 20221 holders, $36m31 holders, $46.6bn
Q1 2023none listed holders, n.a.33 holders, $44.3bn
Q2 2023none listed holders, n.a.37 holders, $59.6bn
Q3 20233 holders, $33m44 holders, $67.6bn
Q4 20234 holders, $61m45 holders, $73.6bn
Q1 20243 holders, $40m41 holders, $95.3bn
Q2 20244 holders, $32m43 holders, $110bn
Q3 20246 holders, $80m45 holders, $107bn
Q4 20244 holders, $131m46 holders, $93.9bn
Q1 20254 holders, $147m42 holders, $98.4bn
Q2 20255 holders, $160m43 holders, $93.2bn
Q3 20259 holders, $496m39 holders, $86.7bn
Q4 202510 holders, $537m41 holders, $123bn
Q1 20267 holders, $450m39 holders, $106bn
Q2 20269 holders, $859m44 holders, $132bn
RYTM

Rhythm Pharmaceuticals Inc

Holders
7
Reported value
$450m
Buyers
18
Sellers
14

Breadth +4 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
39
Reported value
$106bn
Buyers
25
Sellers
25

Breadth 0 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 40 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only RYTM (1)

PDT Partners LLC

Only LLY (33)

Acadian Asset Management LLC, AQR Capital Management LLC, ARK Investment Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, ExodusPoint Capital Management LP, Fidelity (FMR LLC), GAMCO Investors Inc, Harris Associates LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, Polen Capital Management LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, and 8 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →